Novartis announces study in NEJM showing Jakavi® was superior to standard therapy
Novartis announced The New England Journal of Medicine published results from the pivotal Phase III clinical trial demonstrating Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy and reduced spleen size in patients with PV. January 28, 2015